Ascendis Pharma Adr Representing

Ascendis Pharma A/S develops TransCon‑based therapeutics for rare endocrine disorders, including SKYTROFA (growth hormone replacement) and YORVIPATH (hypoparathyroidism), with a Phase III‑validated pipeline poised for growth and oncology expansion.

Headquarters: Denmark (DNK)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 1,017
HQ: Hellerup

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
ASND	Ascendis Pharma Adr Representing Cap: 14.3B	EQUITY	NMS	USD	US04351P1012	Active	📈